159 related articles for article (PubMed ID: 10929446)
1. [Therapy of glucocorticoid-induced osteoporosis with alfacalcidol/calcium and vitamin D/calcium].
Ringe JD; Cöster A; Meng T; Schacht E; Umbach R
Z Rheumatol; 2000 Jun; 59(3):176-82. PubMed ID: 10929446
[TBL] [Abstract][Full Text] [Related]
2. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis.
Ringe JD; Dorst A; Faber H; Schacht E; Rahlfs VW
Rheumatol Int; 2004 Mar; 24(2):63-70. PubMed ID: 14513268
[TBL] [Abstract][Full Text] [Related]
3. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
Ringe JD; Faber H; Fahramand P; Schacht E
J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
[TBL] [Abstract][Full Text] [Related]
4. Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium.
Ringe JD; Cöster A; Meng T; Schacht E; Umbach R
Calcif Tissue Int; 1999 Oct; 65(4):337-40. PubMed ID: 10485988
[TBL] [Abstract][Full Text] [Related]
5. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Ringe JD; Farahmand P; Schacht E; Rozehnal A
Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
[TBL] [Abstract][Full Text] [Related]
6. Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients.
Ringe JD; Farahmand P; Schacht E
Rheumatol Int; 2013 Mar; 33(3):637-43. PubMed ID: 22527138
[TBL] [Abstract][Full Text] [Related]
7. Potential of alfacalcidol for reducing increased risk of falls and fractures.
Ringe JD; Schacht E
Rheumatol Int; 2009 Aug; 29(10):1177-85. PubMed ID: 19159932
[TBL] [Abstract][Full Text] [Related]
8. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
Reginster JY; Lecart MP; Richy F
J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
[TBL] [Abstract][Full Text] [Related]
9. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA).
Matsumoto T; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Nakano T; Ito M; Tomomitsu T; Hirakawa A; Soen S
J Bone Miner Metab; 2020 Jul; 38(4):522-532. PubMed ID: 32140784
[TBL] [Abstract][Full Text] [Related]
10. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study.
Soen S; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Ito M; Nakano T; Hagino H; Hirakawa A; Matsumoto T
J Bone Miner Metab; 2020 Jul; 38(4):511-521. PubMed ID: 31970477
[TBL] [Abstract][Full Text] [Related]
11. Glucocorticoid-induced osteoporosis: is the bone density decrease the only explanation?
Lespessailles E; Poupon S; Adriambelosoa N; Pothuaud L; Siroux V; Bouillon S; Benhamou CL
Joint Bone Spine; 2000; 67(2):119-26. PubMed ID: 10769104
[TBL] [Abstract][Full Text] [Related]
12. High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial.
Hoes JN; Jacobs JW; Hulsmans HM; De Nijs RN; Lems WF; Bruyn GA; Geusens PP; Bijlsma JW
Clin Exp Rheumatol; 2010; 28(3):354-9. PubMed ID: 20406615
[TBL] [Abstract][Full Text] [Related]
13. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.
Sambrook PN; Kotowicz M; Nash P; Styles CB; Naganathan V; Henderson-Briffa KN; Eisman JA; Nicholson GC
J Bone Miner Res; 2003 May; 18(5):919-24. PubMed ID: 12733733
[TBL] [Abstract][Full Text] [Related]
14. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
15. Alfacalcidol versus plain vitamin D in inflammation induced bone loss.
Scharla SH; Schacht E; Lempert UG
J Rheumatol Suppl; 2005 Sep; 76():26-32. PubMed ID: 16142848
[TBL] [Abstract][Full Text] [Related]
16. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.
Ringe JD; Dorst A; Faber H; Ibach K; Preuss J
Rheumatology (Oxford); 2003 Jun; 42(6):743-9. PubMed ID: 12730532
[TBL] [Abstract][Full Text] [Related]
17. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.
Buckley LM; Hillner BE
J Rheumatol; 2003 Jan; 30(1):132-8. PubMed ID: 12508402
[TBL] [Abstract][Full Text] [Related]
18. Calcium, vitamin D and etidronate for the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases.
Loddenkemper K; Grauer A; Burmester GR; Buttgereit F
Clin Exp Rheumatol; 2003; 21(1):19-26. PubMed ID: 12673885
[TBL] [Abstract][Full Text] [Related]
19. [Glucocorticoid induced osteoporosis].
Lange U; Müller-Ladner U
Orthopade; 2007 Apr; 36(4):381-8; quiz 389-90. PubMed ID: 17665509
[TBL] [Abstract][Full Text] [Related]
20. Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis.
Nuti R; Bianchi G; Brandi ML; Caudarella R; D'Erasmo E; Fiore C; Isaia GC; Luisetto G; Muratore M; Oriente P; Ortolani S
Rheumatol Int; 2006 Mar; 26(5):445-53. PubMed ID: 16283320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
